Feasibility of albumin binding modulation in FAP-targeting radiopharmaceuticals: insights from molecular docking and experimental analysis Authors: Sudabeh Shokrollahi, Ahmad Amiri Published: 2025 ABSTRACT AbstractBackgroundUnderstanding the interaction between radiopharmaceuticals and human serum albumin (HSA) is essential for optimizing pharmacokinetics and therapeutic efficacy. This study evaluated the binding properties of natLu-FAPi-46 and natLu-FAP-2286 to HSA using theoretical and experimental techniques.ResultsDocking results revealed moderate affinities for natLu-FAPi-46 (− 9.7 kcal/mol) and natLu-FAP-2286 (− 7.8 kcal/mol), correlating with their lower blood retention (0.43% and 0.03% I.A./g at 4 h p.i.). Comparative docking of albumin-binding derivatives of FAPi-46 showed stronger binding, consistent with increased blood retention. Experimental analyses (fluorescence quenching, circular dichroism, and cyclic voltammetry) confirmed complex formation and conformational changes in HSA, validating the computational findings.ConclusionsTogether, the computational and experimental results underscore the importance of albumin-binding in shaping the pharmacokinetic properties of FAP-targeted radiopharmaceuticals. Strategic optimization of albumin-binding linkers may improve stability, circulation time, and overall therapeutic performance in next-generation FAP-based agents.Graphical abstract Supplementary InformationThe online version contains supplementary material available at 10.1186/s41181-025-00417-9.Keywords: HSA binding, FAP-targeted radiopharmaceuticals, Molecular docking, Blood retention time, Pharmacokinetics optimization Background A molecular target called activation protein for fibroblasts (FAP) is being explored as a promising cancer-diagnosis and therapy tool due to its overexpression in tumor-associated fibroblasts that play an important role in tumor growth, metastasis, and treatment resistance (Lindner et al. 2021; Rezaei et al. 2023; Sun et al. 2024). It has been shown that radiolabeled fibroblast activation protein inhibitors (FAPi) have excellent imaging capabilities and potential therapeutic applications in a wide variety of cancer types (Song et al. 2024; Banihashemian et al. 2024a, b, c, d, 2025). In therapeutic settings, FAPi-based radiopharmaceuticals are limited in effectiveness by rapid clearance and short retention times (Privé et al. 2023). Scientists have explored chemical modifications to improve pharmacokinetic properties and therapeutic efficacy, including albumin-binding strategies (Xu et al. 2022). FAPi-based radiopharmaceuticals can be optimized through conjugation with albumin binders, such as ibuprofen, Evans blue, and 4-(p-iodophenyl) butyric acid (Millul et al. 2023a; Younis et al. 2022; Saito et al. 2025). Human serum albumin (HSA), the predominant protein found in plasma, functions as a natural carrier that extends the circulation time of drugs and radiotracers in the body (Shokrollahi et al. 2022; Li et al. 2025). When HSA-binding moieties are incorporated into FAPi molecules, their retention time increases in the bloodstream, resulting in enhanced tumor accumulation due to the enhanced permeability and retention (EPR) effect (Li et al. 2022). As a result of this modification, a higher dose delivery to the tumor can be achieved while reducing off-target clearance and systemic toxicities (Younis et al. 2022). Millul et al. reported that [177Lu]Lu-FAP-2286 exhibited a higher tumor-to-background ratio (TBR) and greater tumor specificity, particularly in high FAP-expressing tumors, though it demonstrated high kidney uptake. In contrast, [177Lu]Lu-FAPI-46 showed a lower TBR but more consistent uptake across different tumor models. When albumin binders were attached to [177Lu]Lu-FAPI-46, the outcomes varied: [177Lu]Lu-FAPI-46-EB displayed increased tumor retention but also elevated background uptake, whereas [177Lu]Lu-FAPI-46-Ibu exhibited faster clearance without significant improvement in TBR. These findings suggest that while albumin binding can enhance tumor retention, its effect on non-specific uptake depends on the specific binding moiety used (Millul et al. 2023a). Saito et al. designed a novel FAP-2286 derivative, DOTAGA-FAP-2286-ALB, by incorporating the albumin-binding moiety 4-(p-iodophenyl)butyric acid (IPBA) and substituting DOTA with DOTAGA, a chelator known for forming more stable complexes with M3+ radiometals. Their study demonstrated that [111In]In-DOTAGA-FAP-2286-ALB exhibited improved plasma stability, stronger albumin binding, higher FAP-binding affinity, and markedly enhanced tumor retention compared to its non-albumin-bound counterpart. These modifications led to a significant increase in predicted tumor uptake, highlighting the efficacy of albumin binder incorporation as a strategy to prolong circulation time and improve therapeutic payload delivery to tumors (Saito et al. 2025)​. Therefore, studying and understanding the mechanism of interaction between these molecules and HSA at the molecular level is essential to optimize their design for clinical applications. This study, for the first time, aims to investigate the feasibility, binding mechanism, and affinity of natLu complexes of FAPi-46 (as the reference small molecule) and FAP-2286 (as the representative peptide-based radioligand) with HSA using both experimental and computational approaches. Methods Commercially lyophilized HSA (∼99% purity, fatty acid-free ~ 0.005%, essentially globulin-free) was purchased from Sigma Aldrich and used without further purification. The synthesis of natLu complexes, along with their analytical characterization (HPLC chromatograms are shown in Fig. S1), is detailed in the Supplementary Information. Chemical structures of the studied FAPi compounds are shown in Fig. S2. Results Experimental studies on HSA UV–vis absorption studies of HSA conformational stability UV–Vis spectroscopy serves as an essential method for studying the binding interactions between HSA and various compounds (Shokrollahi et al. 2020). In this study, we conducted UV–Vis absorption experiments to examine the effects of natLu-FAPi-46 and natLu-FAP-2286 on HSA stability. The experiment focused on the structural perturbation of HSA in the presence of these two complexes. HSA possesses aromatic residues such as phenylalanine (Phe), tyrosine (Tyr), and tryptophan (Trp), which contribute to a characteristic absorbance peak at 280 nm. This spectral feature is highly responsive to alterations in protein structure, making UV–Vis spectroscopy an effective approach for assessing HSA conformational stability. During the conformational stability study, absorbance at 280 nm was recorded at two temperatures (27 °C and 37 °C) across varying concentrations of natLu-FAPi-46 and natLu-FAP-2286. The unfolding profiles for natLu-FAPi-46 and natLu-FAP-2286 are shown in Fig. 1a and b, respectively, demonstrating that both were capable of inducing HSA unfolding at micromolar concentrations. Additionally, the [L]1/2 values decreased as the temperature increased, likely due to reduced HSA stability at higher temperatures. A lower [L]1/2 value corresponds to higher unfolding efficiency and potentially lower side effects. Unfolding profiles and thermodynamic parameters of HSA in the presence of natLu-FAPi-46 and natLu-FAP-2286. a-b Absorbance changes of HSA at λmax = 280 nm as a function of increasing concentration of the complexes. a natLu-FAPi-46 (left) and b natLu-FAP-2286 (right) at 27 °C (circles) and 37 °C (triangles). c-f Molar Gibbs free energy plots (ΔG° vs [L]t) for HSA unfolding in the presence of natLu-FAPi-46 (left) and natLu-FAP-2286 (right) at 27 °C and 37 °C. g-h Molar enthalpy (ΔH°) plots for HSA unfolding upon interaction with natLu-FAPi-46 (left) and natLu-FAP-2286 (right) over the temperature range of 27–37 °C To further understand the thermodynamic aspects of HSA unfolding caused by these complexes, key parameters such as the unfolding equilibrium constant (K), Gibbs free energy change (ΔG°), enthalpy change (ΔH°), and entropy change (ΔS°) were calculated and summarized in Table 1. The negative slope of the ΔG° curves (see Fig. 1(c–f)) suggests that the binding interactions occur spontaneously. Table 1 Thermodynamic parameters for HSA unfolding induced by natLu-FAPi-46 and natLu-FAP-2286CompoundT (°C)[L]1/2 (µM)ΔG°H2OΔH°H2OΔS°H2OnatLu-FAPi-46272.2919.42640.82372.4210.6natLu-FAP-2286271.638.36 − 139 − 0.49371.9513.4 Thermodynamic parameters for HSA unfolding induced by natLu-FAPi-46 and natLu-FAP-2286 Interestingly, the effect of temperature on ΔG° varied between the two complexes. For natLu-FAPi-46, the ΔG° value decreased from 19.35 kJ/mol at 27 °C to 10.58 kJ/mol at 37 °C, indicating reduced stability with increasing temperature. This trend is consistent with typical macromolecular unfolding, where proteins become less stable at higher temperatures. However, for natLu-FAP-2286, the ΔG° value increased from 8.36 kJ/mol at 27 °C to 13.41 kJ/mol at 37 °C, suggesting a stabilization effect at elevated temperatures. This difference from the expected trend could be attributed to stronger binding interactions or conformational adaptations that enhance the stability of the HSA complex at higher temperatures. As illustrated in Fig. 1g and h, the enthalpy change (ΔH°) of HSA unfolding exhibits opposing trends for natLu-FAPi-46 and natLu-FAP-2286. For natLu-FAPi-46, the positive ΔH° value (263.76 kJ/mol) suggests that unfolding requires significant heat input, indicating strong intermolecular interactions that stabilize the complex. In contrast, natLu-FAP-2286 shows a negative ΔH° (− 138.99 kJ/mol), implying that the unfolding process is exothermic, which may result from weaker binding or structural destabilization. Furthermore, the entropy change (ΔS°) shows contrasting trends for the two complexes. natLu-FAPi-46 has a positive ΔS° (0.82 kJ/mol·K), suggesting increased disorder upon binding, which is typically associated with stronger interactions disrupting the structured protein conformation. Conversely, natLu-FAP-2286 exhibits a negative ΔS° (− 0.49 kJ/mol·K), indicating a more ordered system upon complex formation, possibly due to conformational constraints imposed by ligand binding. These contrasting thermodynamic behaviors highlight fundamental differences in the interaction of the two complexes with HSA, influencing its structural stability and unfolding process. Fluorescence spectroscopy To gain insight into the mechanism of HSA interaction with natLu-FAPi-46 and natLu-FAP-2286, fluorescence quenching studies were conducted. Figure 2a and b display the fluorescence emission spectra of HSA recorded with increasing concentrations of natLu-FAPi-46 and natLu-FAP-2286, respectively. The emission peak of HSA diminished with the addition of these complexes, indicating the formation of a complex between HSA and the compounds. As seen, HSA displays a fluorescence emission peak at 343 nm when excited at 295 nm. Upon titration with increasing concentrations of natLu-FAPi-46 and natLu-FAP-2286, a gradual reduction in the fluorescence intensity was observed. The observed decrease in fluorescence intensity implies significant interactions between the complexes and HSA, likely due to structural alterations near the Trp-214 residue that enhance its quenching (Wang et al. 2007). This reduction in fluorescence may involve a combination of static and dynamic quenching processes. Dynamic quenching refers to the interaction between the fluorophore and quencher during the excited state, while static quenching occurs when a non-fluorescent ground-state complex is formed between the fluorophore and quencher. To differentiate between static and dynamic quenching of HSA by natLu-FAPi-46 and natLu-FAP-2286, the Stern–Volmer equation was applied (Eslami Moghadam et al. 2016): where F0 and F are the fluorescence intensities of HSA in the absence or presence of the quencher, respectively; Kq is the quenching rate constant; Ksv is the Stern–Volmer quenching constant; τ0 = 10–8 s is the average lifetime of the molecule without the quencher; and [L] represents the natLu complexes concentration. The Stern–Volmer plots of F0/F vs. [L] for fluorescence quenching of HSA by natLu-FAPi-46 and natLu-FAP-2286 are shown in Fig. 2c and d. As summarized in Table 2, the calculated Kq values were found to be 1.32 × 1012 and 1.10 × 1012 M−1 s−1 for natLu-FAPi-46 and natLu-FAP-2286, respectively. These values exceed the diffusion-controlled quenching limit (2.0 × 1010 M⁻1 s⁻1), suggesting that static quenching predominates through ground-state complex formation (Shokrollahi and Amiri 2026). a-b Fluorescence emission spectra of HSA in the presence of increasing concentrations of natLu-FAPi-46 (a) and natLu-FAP-2286 (b). c-d Stern–Volmer plots of F0/F versus [L] for fluorescence quenching of HSA by natLu-FAPi-46 (c) and natLu-FAP-2286 (d). e–f Plots of log[(F0−F)/F] versus log[L] for titration of HSA by increasing concentrations of natLu-FAPi-46 (e) and natLu-FAP-2286 (f). Left plots correspond to natLu-FAPi-46 and right plots correspond to natLu-FAP-2286 Table 2Ster-Volmer quenching constants (Ksv), quenching rates (Kq), binding constants (Ka), and the number of binding sites (n) for the interaction of HSA with natLu-FAPi-46 and natLu-FAP-2286 complexesSystemKsv (M−1)Kq (M−1 s−1)Ka (M−1)Kd (µM)nHSA-natLu-FAPi-461.32 × 1041.32 × 10123.22 × 10431.21.23HSA-natLu-FAP-22861.10 × 1041.10 × 10121.22 × 10482.01.03 Ster-Volmer quenching constants (Ksv), quenching rates (Kq), binding constants (Ka), and the number of binding sites (n) for the interaction of HSA with natLu-FAPi-46 and natLu-FAP-2286 complexes The Kq values for both complexes are two orders of magnitude higher than the diffusion-controlled limit, confirming that the quenching mechanism is exclusively static quenching through the formation of non-fluorescent ground-state complexes between HSA and the ligands. This indicates strong, specific binding interactions rather than transient collisional encounters. The results indicate that both complexes interact with HSA through a static quenching mechanisms, with natLu-FAPi-46 showing a relatively stronger interaction than natLu-FAP-2286 based on the higher Kq​ value. However, further studies would be required to definitively distinguish the relative contributions of these mechanisms in each case. To determine the binding constant and number of binding sites, the Stern–Volmer equation was further applied (Instrumentation for Fluorescence Spectroscopy and Lakowicz 2006): where F0​ and F are as defined previously, Ka ​ is the binding constant, n is the number of binding sites, and [L] is the concentration of the complexes. The values of Ka and n were obtained from plots of log[(F0 − F)/F] vs. log[L] (see Figs. 2(e) and (f)), and the results are summarized in Table 2. The binding constants (Ka​) were 3.22 × 104 M−1 for natLu-FAPi-46 and 1.22 × 104 M−1 for natLu-FAP-2286, corresponding to dissociation constants (Kd​) of 31.1 µM and 82.0 µM, respectively. These values indicate moderate binding affinity to HSA, with natLu-FAPi-46 exhibiting approximately 2.6-fold stronger binding than natLu-FAP-2286. The n values were found to be 1.23 and 1.03 for natLu-FAPi-46 and natLu-FAP-2286, respectively, suggesting a single binding site for each complex in the HSA structure. Circular dichroism Circular dichroism (CD) spectroscopy is a powerful tool for investigating changes in the secondary structure of HSA upon its interaction with different ligands (Eslami Moghadam et al. 2024). The far-UV CD spectra, typically ranging from 190 to 260 nm, provides valuable information on conformational alterations in proteins. Figure 3a and b show the far-UV CD spectra of HSA, both in the absence and presence of the natLu-FAPi-46 and natLu-FAP-2286 complexes. The CD spectra of HSA show two negative peaks at 208 and 222 nm, which correspond to the n → π* and π → π* transitions of the peptide bonds. The peak at 208 nm is particularly indicative of the α-helical structure of the protein. a-b Far-UV CD spectra and secondary structure analysis of HSA in the absence and presence of natLu-FAPi-46 (left) and natLu-FAP-2286 (right). c–d Changes in the α-helix, β-sheet, and random coil content of HSA following complexation Upon binding at increasing concentrations of the complexes, the overall shape of the CD spectra remains relatively unchanged, suggesting that the interaction with natLu-FAPi-46 and natLu-FAP-2286 does not drastically affect the secondary structure of HSA. However, a decrease in the intensity of the negative bands was observed compared to the pure HSA spectra. This suggests a reduction in α-helical content and a concomitant increase in β-sheet and random coil structures after complexation with the ligands. The percentages of α-helix, β-sheet, and random coil structures were determined using the CDNN program and are shown in Fig. 3c and d. These results suggest that binding of natLu-FAPi-46 and natLu-FAP-2286 causes partial unfolding of HSA, leading to the exposure of buried hydrophobic regions. Additionally, an inverse trend was observed between the random coil and α-helix components. Specifically, the random coil fraction increased as the α-helix content decreased upon complex formation. The CDNN analysis quantitatively confirms these structural changes, showing a progressive decrease in α-helical content with increasing ligand concentration. For natLu-FAPi-46, the α-helix fraction decreased from 66.1 to 45.2%, while for natLu-FAP-2286, it declined from 72 to 57.8%. This reduction was accompanied by an increase in random coil and β-sheet structures, indicating partial unfolding and exposure of hydrophobic regions. Notably, natLu-FAPi-46 caused a more pronounced structural perturbation compared to natLu-FAP-2286, suggesting a stronger interaction with HSA. These findings highlight the impact of ligand binding on the conformational stability of HSA, which may influence its biological function and binding affinity for other molecules. Cyclic voltammetry Cyclic voltammetry (CV) serves as a powerful and versatile electrochemical technique for exploring the interactions between proteins and drug molecules. It allows for real-time monitoring of redox behavior and binding events under conditions that closely resemble the physiological environment, providing valuable insights into the nature and strength of these interactions (Huang et al. 2014). To further validate the results from spectroscopic methods, CV was employed to investigate the interaction of natLu-FAPi-46 and natLu-FAP-2286 with HSA using a gold electrode. The HSA-modified gold electrode was first characterized using the K3Fe(CN)6/K4Fe(CN)6 redox probe, which exhibits distinct electrochemical behavior on different surfaces. As shown in Fig. 4a and b, a pair of reversible redox peaks was observed on both the bare gold electrode and the HSA-modified electrode. However, after HSA immobilization, the redox peak potentials shifted negatively, and the redox peak currents decreased significantly. This indicated that HSA modification altered the electrochemical properties of the electrode surface. An increase in the redox peak potential difference from 84 to 97 mV, accompanied by a decline in peak current from 83.4 µA to 80.7 µA, suggests a slowdown in electron transfer efficiency and a decrease in conductivity (Huang et al. 2014). Cyclic voltammetry results for HSA-modified gold electrodes in K3Fe(CN)6/K4Fe(CN)6 solution. a shows redox peaks for natLu-FAPi-46 and b for natLu-FAP-2286. c Peak current and d peak potential changes as a function of natLu complex concentration The HSA-modified electrode was then used to investigate the interaction with natLu-FAPi-46 and natLu-FAP-2286. Upon the addition of a 100 µM solution of the complexes to the K3Fe(CN)6/K4Fe(CN)6 electrolyte, a concentration-dependent decrease in redox peak currents was observed, with slight shifts in peak potentials. The concentration of the complexes increased progressively from 1.57 to 8.76 µM over six additions, and the current did not recover after washing the electrode, confirming the formation of stable complexes with HSA. Comparative analysis revealed distinct electrochemical behaviors between the two complexes. natLu-FAP-2286 exhibited a higher initial redox current than natLu-FAPi-46, but the current decreased more rapidly with increasing concentration, suggesting stronger inhibition of electron transfer. natLu-FAPi-46 caused more significant shifts in peak potentials, suggesting more pronounced conformational changes in HSA. Both complexes exhibited strong drug-protein interactions, but the effects were more pronounced for natLu-FAP-2286. The changes in peak potential and peak current as a function of concentration are shown in Fig. 4c and d, respectively, providing a clear comparison of the two complexes' interactions with HSA. Molecular docking Molecular docking was performed to investigate the interaction of natLu-FAPi-46 and natLu-FAP-2286 with human serum albumin (HSA) and to provide structural insights into their binding affinity and interaction mechanisms. While previous studies have explored albumin-binding modifications of FAPi-46 to enhance circulation time, this study focused solely on the parent compound (natLu-FAPi-46) and the peptide-based FAP-targeting agent (natLu-FAP-2286). For comparative analysis, docking results were evaluated in conjunction with experimental findings and literature data on albumin-binding derivatives of FAPi-46 (Millul et al. 2023a). Due to the computational challenges associated with accurately modeling lutetium-coordinated complexes in docking studies, and to avoid false positive results arising from non-specific interactions of the carboxylate groups in the DOTA chelator, the docking simulations were performed on the DOTA-free ligand structures (see SI for details). This approach allowed for a more precise evaluation of the vector and linker effects on albumin binding, independent of metal coordination artifacts. The docking results revealed a wide range of binding affinities, with FAPi-46 (− 9.7 kcal/mol) and FAP-2286 (− 7.8 kcal/mol) exhibiting moderate interactions with HSA, correlating with their relatively low blood retention values (0.43% and 0.03% I.A./g at 4 h p.i.) (Millul et al. 2023b). In contrast, albumin-binding derivatives of FAPi-46 demonstrated significantly stronger binding, as seen with FAPi-46-F1 (− 10.5 kcal/mol, 0.62% I.A./g), FAPi-46-Ibu (− 10.9 kcal/mol, 1.07% I.A./g), and FAPi-46-F1D (− 12.1 kcal/mol, 1.21% I.A./g) (Millul et al. 2023b). The strongest binding was observed for FAPi-46-EB (− 13.3 kcal/mol, 11.59% I.A./g), highlighting the impact of albumin-targeting linkers on increasing HSA affinity and circulation time. These trends are further illustrated in Fig. 5, where a clear inverse correlation between binding affinity and blood retention is observed, reinforcing the role of albumin-binding modifications in prolonging systemic circulation. Comparison of binding energy and blood retention for FAP-targeting radiopharmaceuticals Ligand interaction analysis using LigPlot + (Fig. 6) further demonstrated key binding interactions. FAPi-46-EB formed extensive hydrogen bonds with residues such as Trp-214, Arg-218, and Tyr-150, stabilizing its interaction at Sudlow’s site I, the primary albumin binding pocket. FAPi-46-F1D and FAPi-46-Ibu derivatives displayed mixed hydrogen bonding and hydrophobic interactions, contributing to their intermediate binding affinities and moderate blood retention. In contrast, FAP-2286, which lacks a strong albumin-binding linker, exhibited predominantly hydrophobic interactions and the weakest docking affinity, corresponding to its rapid clearance. Hydrogen bonds and hydrophobic interactions are depicted for a FAPi-46, b FAPi-46-F1, c FAPi-46-EB, d FAPi-46-F1D, e FAPi-46-Ibu, and f FAP-2286 within the HSA binding pocket. Hydrogen bonds are shown as green dashed lines, while hydrophobic contacts are represented by spoked arcs around interacting residues Experimental spectroscopy and electrochemical studies provided additional insights into the interactions of natLu-FAPi-46 and natLu-FAP-2286 with HSA. Fluorescence quenching confirmed complex formation, while circular dichroism (CD) spectroscopy revealed partial unfolding of HSA, with natLu-FAPi-46 inducing greater structural changes than natLu-FAP-2286. Cyclic voltammetry (CV) showed significant perturbations in electron transfer upon complexation with HSA, supporting the formation of stable interactions. These findings correlate well with docking results, where natLu-FAPi-46 exhibited stronger binding than natLu-FAP-2286, consistent with its greater influence on HSA stability. The combination of docking and experimental data for natLu-FAPi-46 and natLu-FAP-2286, along with literature comparisons for albumin-binding derivatives, underscores the critical role of albumin interactions in determining pharmacokinetics. These findings provide a structural and functional basis for optimizing future FAP-targeting radiopharmaceuticals through albumin-binding modifications. Discussion The combined experimental and computational findings provide complementary insights into how FAP-targeting radiopharmaceuticals interact with human serum albumin (HSA). Both natLu-FAPi-46 and natLu-FAP-2286 exhibited moderate binding affinities, suggesting that direct albumin interaction contributes modestly to their blood retention. These results align with previous studies showing that unmodified FAP ligands clear rapidly from circulation due to weak albumin association (Millul et al. 2023a; Saito et al. 2025). The spectroscopic data confirm that binding of both compounds induces conformational changes in HSA. The partial unfolding observed in CD spectra, accompanied by decreased α-helical content, reflects protein structural perturbations typically associated with ligand binding. Interestingly, natLu-FAPi-46 caused more pronounced conformational alterations than natLu-FAP-2286, consistent with its slightly higher binding constant and greater fluorescence quenching efficiency. Thermodynamic parameters further support these observations. The positive ΔH° and ΔS° values for natLu-FAPi-46 indicate that hydrophobic interactions play a major role in complex formation, while the opposite trend for natLu-FAP-2286 suggests contributions from hydrogen bonding or electrostatic forces. Together, these findings imply that small-molecule FAP inhibitors interact more flexibly with albumin than their peptide-based counterparts. Electrochemical studies reinforced these conclusions. The decrease in redox peak current and shift in potential upon complex addition reflect hindered electron transfer at the HSA-modified electrode, evidencing strong complex formation at the protein surface. Docking simulations provided a structural rationale for these results. The moderate binding energies (− 9.7 and − 7.8 kcal/mol) correlate well with the experimental data and reported pharmacokinetic behaviors of these compounds. Comparative docking with albumin-binding derivatives (such as FAPi-46-EB and FAPi-46-Ibu) confirmed that the inclusion of albumin-binding linkers markedly enhances HSA affinity, explaining the extended blood retention observed in vivo. Fluorescence quenching yielded dissociation constants (Kd) of 31.1 µM for natLu-FAPi-46 and 82.0 µM for natLu-FAP-2286, consistent with their moderate docking scores and low blood retention. Overall, these results emphasize the importance of rational albumin-binding optimization in the design of FAP-targeted radiopharmaceuticals. Incorporating appropriately tuned linkers can improve systemic stability, tumor uptake, and therapeutic index, while avoiding excessive background retention. Conclusion This study provides a comprehensive structural and experimental analysis of the interactions between natLu-FAPi-46 and natLu-FAP-2286 with human serum albumin (HSA). Molecular docking revealed moderate binding affinities, which correlated with the lower blood retention and weaker albumin interactions observed in experimental assays. Comparative docking with albumin-binding derivatives of FAPi-46 further confirmed that stronger albumin interactions correlate with prolonged circulation times, as supported by literature data. Experimental results, including fluorescence quenching, circular dichroism, and cyclic voltammetry, validated the computational findings by demonstrating distinct differences in HSA conformational stability and electrochemical properties between the two studied compounds. Overall, this study emphasizes the critical role of albumin-binding strategies in optimizing radiopharmaceutical pharmacokinetics, offering valuable insights for the rational design of FAP-targeting therapeutics with enhanced stability and systemic retention. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Acknowledgements The University of Tehran is gratefully acknowledged for the financial support of this research. Abbreviations Fibroblast activation protein Fibroblast activation protein inhibitor Human serum albumin Non-radioactive (natural) lutetium complex 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid 1,4,7,10-Tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid 4-(P-iodophenyl)butyric acid Evans blue Ibuprofen Albumin-binding derivatives of FAPi-46 Ultraviolet–visible spectroscopy Circular dichroism Cyclic voltammetry Tryptophan Tyrosine Phenylalanine Gibbs free energy change Enthalpy change Entropy change Stern–volmer quenching constant Quenching rate constant Dissociation constant Binding constant Number of binding sites Ligand concentration Enhanced permeability and retention effect Tumor-to-background ratio Injected activity per gram Post-injection Positron emission tomography / computed tomography Lutetium-177 Gallium-68 Author contributions SS: Methodology, Validation, Formal analysis, Investigation, Data curation, Visualization and Writing—original draft. AA: Conceptualization, Supervision, Project administration, Resources, Formal analysis and Writing—review & editing. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability All data generated or analyzed during this study are included in this published article and its supplementary information files. Declarations Ethics approval and consent to participate Not applicable (no human or animal studies were conducted). Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data generated or analyzed during this study are included in this published article and its supplementary information files.